PRKCQ (Protein Kinase C Theta) Gene
A key regulator of T-cell activation and immune signaling
Gene Information Card
| Symbol | PRKCQ |
|---|---|
| Full Name | protein kinase C theta |
| Gene Type | protein coding |
| Chromosomal Location | 10p15.1 |
| NCBI Gene ID | 5588 ncbi.nlm.nih.gov/gene/5588 |
| Ensembl ID | ENSG00000165675 |
| UniProt ID | Q04759 |
| OMIM ID | 600448 |
| HGNC ID | 9410 |
| Aliases | PKC theta, nPKC-theta, PRKCT |
Description
PRKCQ encodes protein kinase C theta (PKCθ), a serine/threonine kinase of the PKC family that is predominantly expressed in T cells and plays a critical role in T-cell receptor (TCR) signaling, NF-κB activation, and immune synapse formation. It is involved in T-cell activation, differentiation, and survival, and its dysregulation is linked to various cancers and autoimmune diseases.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| T-cell lymphoma | PRKCQ mutations and overexpression drive aberrant T-cell proliferation and survival | PMID: 25605247 |
| Autoimmune diseases (e.g., rheumatoid arthritis, multiple sclerosis) | PKCθ hyperactivation promotes pro-inflammatory T-cell responses | PMID: 21217763 |
| Colorectal cancer | PRKCQ amplification and overexpression contribute to tumor growth via NF-κB signaling | PMID: 24755471 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Spleen | 28.5 | High |
| Lymph node | 22.3 | High |
| Thymus | 18.7 | High |
| Blood | 15.2 | Medium |
| Bone marrow | 10.1 | Medium |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| Jurkat T cells | 35.2 | T-cell leukemia line |
| MOLT-4 | 30.8 | T-cell lymphoblastic leukemia |
| K-562 | 8.5 | Chronic myeloid leukemia |
| HeLa | 2.1 | Cervical carcinoma |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1048C>T (p.Arg350Trp) | Missense | <0.1% | Impaired kinase activity |
| c.1129G>A (p.Glu377Lys) | Missense | <0.1% | Altered substrate specificity |
| c.1582_1583insA (p.Thr528Asnfs*2) | Frameshift | <0.1% | Loss of function |
Mutation functional classification
Loss of Function (LOF)
Frameshift and nonsense mutations that truncate the kinase domain lead to loss of catalytic activity.
Gain of Function (GOF)
Missense mutations in the activation loop (e.g., p.Glu377Lys) may enhance kinase activity and promote oncogenic signaling.
Dominant Negative (DN)
Mutations that disrupt the regulatory domain while retaining the catalytic domain can act as dominant-negative inhibitors.
View complete mutation data：
Gene Ontology (GO)
| • GO:0004697 (protein kinase C activity) | • GO:0005524 (ATP binding) |
| • GO:0007165 (signal transduction) | • GO:0045087 (innate immune response) |
| • GO:0050852 (T cell receptor signaling pathway) |
Pathways
• T cell receptor signaling pathway (KEGG hsa04660)
• NF-kappa B signaling pathway (KEGG hsa04064)
• Fc epsilon RI signaling pathway (KEGG hsa04664)
Protein Summary
Protein kinase C theta (PKCθ) is a 706-amino acid serine/threonine kinase with a C-terminal kinase domain, a regulatory domain containing C1 and C2-like domains, and a V3 hinge region. It is essential for T-cell activation by phosphorylating downstream targets such as CARMA1, leading to NF-κB activation. PKCθ also regulates cytoskeletal reorganization at the immune synapse and influences T-cell differentiation into Th1, Th2, or Th17 subsets.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PRKCQ Knockout HEK293 Cell Line | EDJ-KQ585 | Human | 5588 | Details Get a Quote |
| PRKCQ Knockout A-549 Cell Line | EDJ-KQ19006 | Human | 5588 | Details Get a Quote |
| PRKCQ Knockout HeLa Cell Line | EDJ-KQ54213 | Human | 5588 | Details Get a Quote |
| PRKCQ Knockout HCT 116 Cell Line | EDJ-KQ71178 | Human | 5588 | Details Get a Quote |
| PRKCQ Knockout HAP1 Cell Line | EDC08158 | Human | 5588 | Details Get a Quote |
Displaying Records 1 To 5 Of 5 Records
